Inventiva Act Po SEC Filings

Inventiva S.A. is calling shareholders to a Combined General Meeting on June 30, 2026 in Paris and has made all preparatory documents available on its website and at its registered office.

The agenda has been expanded with a 39th resolution linked to a master agreement signed with the European Investment Bank. Inventiva plans to fully repay existing EIB loans, repurchase and cancel certain existing EIB warrants for an aggregate price of €50 million, and issue new warrants to the EIB on more standard terms, subject to shareholder approval at the meeting or, if needed, at a later meeting held by October 31, 2026.

Inventiva S.A. has informed investors that it has started mailing a proxy card and voting instructions to beneficial owners of its American Depositary Shares for its Ordinary and Extraordinary General Meeting. The meeting will take place on June 30, 2026 at 2 p.m. in Paris, France.

ADS holders can review the meeting materials on the company’s website or request free physical copies by mail. They may submit their votes by returning a completed voting form in a postage-paid envelope and are encouraged to consult their brokers for detailed voting guidance.

Inventiva S.A. has informed investors that it has started mailing a proxy card and voting instructions to beneficial owners of its American Depositary Shares for its Ordinary and Extraordinary General Meeting. The meeting will take place on June 30, 2026 at 2 p.m. in Paris, France.

ADS holders can review the meeting materials on the company’s website or request free physical copies by mail. They may submit their votes by returning a completed voting form in a postage-paid envelope and are encouraged to consult their brokers for detailed voting guidance.

Inventiva S.A. has launched a comprehensive refinancing to support its MASH program and upcoming Phase 3 NATiV3 readout. The company is issuing 27,272,727 ADSs at $4.40 each, raising expected net proceeds of about $110.8 million (€95.2 million). It will use this cash, together with new debt, to fully repay its approximately €63 million European Investment Bank loan and repurchase a portion of related warrants that could otherwise convert into 38,360,540 shares.

Inventiva also agreed a secured structured debt facility with BlackRock and Claret of up to €130 million in committed tranches, plus a €20 million uncommitted tranche, with an initial €75 million draw. The debt carries fixed interest near 9.9%, runs to 2030, and is backed by key assets, including lanifibranor patents. Lenders receive equity-linked warrants, and the financing includes covenants and default triggers tied to NATiV3 Phase 3 results and market capitalization. Assuming completion of the equity raise, EIB transactions and Tranches A and B, Inventiva expects to fund operations into late Q2 2027, potentially into early Q1 2028 if all additional financing elements, including Tranche C and existing Tranche 3 warrants, are fully utilized.

Inventiva S.A. has launched a comprehensive refinancing to support its MASH program and upcoming Phase 3 NATiV3 readout. The company is issuing 27,272,727 ADSs at $4.40 each, raising expected net proceeds of about $110.8 million (€95.2 million). It will use this cash, together with new debt, to fully repay its approximately €63 million European Investment Bank loan and repurchase a portion of related warrants that could otherwise convert into 38,360,540 shares.

Inventiva also agreed a secured structured debt facility with BlackRock and Claret of up to €130 million in committed tranches, plus a €20 million uncommitted tranche, with an initial €75 million draw. The debt carries fixed interest near 9.9%, runs to 2030, and is backed by key assets, including lanifibranor patents. Lenders receive equity-linked warrants, and the financing includes covenants and default triggers tied to NATiV3 Phase 3 results and market capitalization. Assuming completion of the equity raise, EIB transactions and Tranches A and B, Inventiva expects to fund operations into late Q2 2027, potentially into early Q1 2028 if all additional financing elements, including Tranche C and existing Tranche 3 warrants, are fully utilized.

We are offering 27,272,727 ADSs, each representing one ordinary share. The offering price is $4.40 per ADS for gross proceeds of $119,999,999 and estimated net proceeds of approximately $110.8M (€95.2M). We currently intend to use the net proceeds to repay in full our EIB loans and, together with proceeds from a new debt financing, to fund the repurchase of a portion of the EIB warrants; remaining funds under that debt commitment would fund continued development and potential commercialization of lanifibranor and general corporate purposes. The offering and related financings are interlinked: the Subscription Agreement with BlackRock and Claret and the EIB Master Agreement are conditioned on this equity financing and certain other conditions, and Tranche A/B initial debt closings are expected in mid-June 2026, subject to those conditions.

We are offering 27,272,727 ADSs, each representing one ordinary share. The offering price is $4.40 per ADS for gross proceeds of $119,999,999 and estimated net proceeds of approximately $110.8M (€95.2M). We currently intend to use the net proceeds to repay in full our EIB loans and, together with proceeds from a new debt financing, to fund the repurchase of a portion of the EIB warrants; remaining funds under that debt commitment would fund continued development and potential commercialization of lanifibranor and general corporate purposes. The offering and related financings are interlinked: the Subscription Agreement with BlackRock and Claret and the EIB Master Agreement are conditioned on this equity financing and certain other conditions, and Tranche A/B initial debt closings are expected in mid-June 2026, subject to those conditions.

Inventiva S.A. reported its first quarter 2026 financial information, focusing on cash resources and runway for its MASH program. As of March 31, 2026, cash and cash equivalents were €75.0 million and short-term deposits were €121.5 million, compared with €99.3 million and €131.6 million as of December 31, 2025. The cash use mainly reflects planned spending on the lanifibranor development program.

Based on its current business plan, Inventiva estimates that its cash, cash equivalents and short-term deposits should fund operations until the middle of the first quarter of 2027. If Tranche 3 warrants from its structured financing are fully exercised for up to €116.0 million, the company estimates funding could extend to the middle of the third quarter of 2027, although exercise is not guaranteed. Inventiva reported no revenue for the first quarter of 2026, consistent with the first quarter of 2025, and highlighted topline NATiV3 Phase 3 results as an anticipated milestone in the fourth quarter of 2026.

Inventiva S.A. reported its first quarter 2026 financial information, focusing on cash resources and runway for its MASH program. As of March 31, 2026, cash and cash equivalents were €75.0 million and short-term deposits were €121.5 million, compared with €99.3 million and €131.6 million as of December 31, 2025. The cash use mainly reflects planned spending on the lanifibranor development program.

Based on its current business plan, Inventiva estimates that its cash, cash equivalents and short-term deposits should fund operations until the middle of the first quarter of 2027. If Tranche 3 warrants from its structured financing are fully exercised for up to €116.0 million, the company estimates funding could extend to the middle of the third quarter of 2027, although exercise is not guaranteed. Inventiva reported no revenue for the first quarter of 2026, consistent with the first quarter of 2025, and highlighted topline NATiV3 Phase 3 results as an anticipated milestone in the fourth quarter of 2026.

Inventiva S.A. is convening an ordinary and extraordinary general meeting on June 30, 2026 in Paris and sets out extensive resolutions on 2025 results, governance and future financing tools. Shareholders are asked to approve 2025 statutory and consolidated accounts showing a net accounting loss of EUR 207,965,630.56, to carry this loss forward, bringing the debit balance of retained earnings to EUR 583,594,899.42, and to confirm that no dividend will be paid. The agenda includes say‑on‑pay approvals, renewal and appointment of directors, and a board fee pool of up to EUR 1,500,000. Shareholders are also asked to authorize a share buyback of up to 10% of outstanding shares at a maximum price of EUR 40 per share and to grant multiple capital authorization mandates, including share issues with and without preemptive rights up to a combined nominal cap of EUR 2,000,000 and related debt securities up to EUR 500,000,000. Further resolutions cover employee and officer equity incentives, an at‑the‑market program framework, and potential capital reductions via share cancellations. One resolution notes that shareholders’ equity has fallen below half of share capital and records the decision not to dissolve the company, requiring equity to be restored within the legal timeframe.

Inventiva S.A. is convening an ordinary and extraordinary general meeting on June 30, 2026 in Paris and sets out extensive resolutions on 2025 results, governance and future financing tools. Shareholders are asked to approve 2025 statutory and consolidated accounts showing a net accounting loss of EUR 207,965,630.56, to carry this loss forward, bringing the debit balance of retained earnings to EUR 583,594,899.42, and to confirm that no dividend will be paid. The agenda includes say‑on‑pay approvals, renewal and appointment of directors, and a board fee pool of up to EUR 1,500,000. Shareholders are also asked to authorize a share buyback of up to 10% of outstanding shares at a maximum price of EUR 40 per share and to grant multiple capital authorization mandates, including share issues with and without preemptive rights up to a combined nominal cap of EUR 2,000,000 and related debt securities up to EUR 500,000,000. Further resolutions cover employee and officer equity incentives, an at‑the‑market program framework, and potential capital reductions via share cancellations. One resolution notes that shareholders’ equity has fallen below half of share capital and records the decision not to dissolve the company, requiring equity to be restored within the legal timeframe.

Inventiva S.A. ownership disclosure: Deep Track entities and David Kroin report beneficial ownership of 7,800,465 ordinary shares, representing 3.76% of the class as of March 31, 2026. The filing says the position is calculated using 207,707,475 shares outstanding as of that date.

The reported holdings comprise 6,578,012 Ordinary Shares, 1,222,453 ADS (each ADS = 1 Ordinary Share) and 9,999,999 Warrants exercisable at €1.50 subject to a T3 Triggering Event. The T3 Triggering Event requires topline NATiV3 endpoint results by June 15, 2027; warrant exercise must occur no later than July 30, 2027. The filing is a joint Schedule 13G/A amendment signed May 15, 2026.

Inventiva S.A. ownership disclosure: Deep Track entities and David Kroin report beneficial ownership of 7,800,465 ordinary shares, representing 3.76% of the class as of March 31, 2026. The filing says the position is calculated using 207,707,475 shares outstanding as of that date.

The reported holdings comprise 6,578,012 Ordinary Shares, 1,222,453 ADS (each ADS = 1 Ordinary Share) and 9,999,999 Warrants exercisable at €1.50 subject to a T3 Triggering Event. The T3 Triggering Event requires topline NATiV3 endpoint results by June 15, 2027; warrant exercise must occur no later than July 30, 2027. The filing is a joint Schedule 13G/A amendment signed May 15, 2026.

Inventiva S.A. filed a Form 6-K to share leadership changes as it advances its MASH program. The company appointed Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer.

These executives bring extensive experience in investment banking, biopharma finance, legal, governance, and human resources, including prior roles tied to major M&A and capital markets transactions. Inventiva is preparing for the top-line data readout from its NATiV3 Phase 3 trial of lanifibranor in MASH, expected in the fourth quarter of 2026.

Existing leaders Jean Volatier and Nathalie Harroy will remain with the company in new roles, supporting finance, corporate social responsibility, and human resources as Inventiva plans for potential regulatory submissions and commercialization.

Inventiva S.A. filed a Form 6-K to share leadership changes as it advances its MASH program. The company appointed Axel-Sven Malkomes as Chief Financial Officer, Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer.

These executives bring extensive experience in investment banking, biopharma finance, legal, governance, and human resources, including prior roles tied to major M&A and capital markets transactions. Inventiva is preparing for the top-line data readout from its NATiV3 Phase 3 trial of lanifibranor in MASH, expected in the fourth quarter of 2026.

Existing leaders Jean Volatier and Nathalie Harroy will remain with the company in new roles, supporting finance, corporate social responsibility, and human resources as Inventiva plans for potential regulatory submissions and commercialization.

New Enterprise Associates–affiliated funds report beneficial ownership of 9,372,390 Inventiva S.A. ordinary shares, equal to 4.9% of the class. This Amendment No. 4 to Schedule 13D is being filed because the reporting group fell below the 5% reporting threshold after an increase in Inventiva’s outstanding shares.

NEA 17 holds 6,684,064 ordinary shares plus 1,021,660 Exercisable Shares from T1 BSAs, T1bis BSAs and Pre-Funded Warrants, while GEO holds 1,666,666 ordinary shares and may be deemed to share in the same Exercisable Shares. The group states it acquired the position for investment purposes, reports no transactions in the last 60 days, and disclaims beneficial ownership beyond shares held of record.

New Enterprise Associates–affiliated funds report beneficial ownership of 9,372,390 Inventiva S.A. ordinary shares, equal to 4.9% of the class. This Amendment No. 4 to Schedule 13D is being filed because the reporting group fell below the 5% reporting threshold after an increase in Inventiva’s outstanding shares.

NEA 17 holds 6,684,064 ordinary shares plus 1,021,660 Exercisable Shares from T1 BSAs, T1bis BSAs and Pre-Funded Warrants, while GEO holds 1,666,666 ordinary shares and may be deemed to share in the same Exercisable Shares. The group states it acquired the position for investment purposes, reports no transactions in the last 60 days, and disclaims beneficial ownership beyond shares held of record.

Inventiva reported 2025 full-year results showing revenues of €4.5 million, down from €9.2 million in 2024, and a net loss widening to €354.1 million from €184.2 million. Cash and cash equivalents were €99.3 million and short-term deposits €131.6 million as of December 31, 2025.

The company raised gross proceeds of $172.5 million in a U.S. public offering and €115.6 million from the second tranche of a structured financing, helping extend its cash runway, which it estimates to last until the middle of the first quarter of 2027. Auditors will include a section on material uncertainty related to going concern in their report.

R&D expenses fell 4% to €87.0 million, while general and administrative costs jumped to €47.9 million, driven largely by €20.3 million of share-based compensation linked to governance and organizational changes. A €212.8 million net financial loss, mainly from non-cash fair value adjustments on derivative instruments and warrants, significantly contributed to the overall loss.

Inventiva reported 2025 full-year results showing revenues of €4.5 million, down from €9.2 million in 2024, and a net loss widening to €354.1 million from €184.2 million. Cash and cash equivalents were €99.3 million and short-term deposits €131.6 million as of December 31, 2025.

The company raised gross proceeds of $172.5 million in a U.S. public offering and €115.6 million from the second tranche of a structured financing, helping extend its cash runway, which it estimates to last until the middle of the first quarter of 2027. Auditors will include a section on material uncertainty related to going concern in their report.

R&D expenses fell 4% to €87.0 million, while general and administrative costs jumped to €47.9 million, driven largely by €20.3 million of share-based compensation linked to governance and organizational changes. A €212.8 million net financial loss, mainly from non-cash fair value adjustments on derivative instruments and warrants, significantly contributed to the overall loss.